Czy antagoniści receptorów angiotensynowych AT1 (sartany) mogą zwiększać ryzyko wystąpienia choroby nowotworowej? Komentarz kardiologa i hipertensjologa
Journal Title: OncoReview - Year 2012, Vol 2, Issue 1
Abstract
Authors and Affiliations
Krzysztof Filipiak
Keywords
Related Articles
- EP ID EP53144
- DOI -
- Views 193
- Downloads 0
Selected aspects of gastrointestinal stromal tumors management with tyrosine kinase inhibitors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract that most frequently affect the stomach and small intestine. In the past these tumors may have been misclassifi...
Distress and depression in cancer patients - diagnosis and treatment
Cancer diagnosis destroys previous internal and external order of patient, who has not experienced such a situation yet. The most negative emotions, which are felt in the situation of cancer diagnoses are anxiety, sadnes...
Dylematy w leczeniu raka nerki - pazopanib
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
The mTOR signalling pathways in the pathogenesis and treatment of neuroendocrine tumours
Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms.The majority of patients are diagnosed with locally advanced or metastatic disease, and curative surgery is rarely an option. Treatment approac...
High risk pulmonary embolism in oncology
Pulmonary embolism is a frequent complication of both cancer and the oncologic therapy. There is still discussed the subject of optimal antithrombotic prophylaxis in oncology. This article presents the patient with metas...